#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Intracranial germ cell tumour Rosai-Dorfman syndrome Intracranial calcification Haemolytic uraemic syndrome Gestational trophoblastic tumour Partial lipodystrophy Congenital absence of bile ducts Mantle cell lymphoma recurrent Superficial vein thrombosis Primitive neuroectodermal tumour Renal cell carcinoma Amyotrophic lateral sclerosis Cystic fibrosis Bronchopulmonary dysplasia Carcinoid syndrome More trials…

    Learn about Rare Diseases

    Mitochondrial myopathy Isodicentric chromosome 15 syndrome Hepatoblastoma – Basic Information Osteosarcoma metastatic – Basic Information Hepatic angiosarcoma – Treatment Leiomyosarcoma recurrent – Basic Information Ewing’s sarcoma – Diagnostics Combined immunodeficiency Immunodeficiency congenital – Diagnostics Advanced systemic mastocytosis – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Palonosetron Hydrochloride Levobupivacaine Hydrochloride Mometasone Zinc Sulphate Heptahydrate Pazopanib Ociperlimab Dinutuximab Beta Romidepsin Itacitinib Doxylamine Hydrogen Succinate Iomeprol Lenalidomide Ltx-315 Fluticasone Propionate Epirubicin Hydrochloride ORX750 Lysine Acetate VOTOPLAM Anhydrous Glucose Bp Deferiprone More therapies…

    Learn about Your Condition

    Brain neoplasm malignant Endometrial cancer stage I Prodromal Alzheimer's disease Plasmablastic lymphoma Infertility male Pulmonary congestion Proteinuria Renal failure Bladder cancer recurrent Hepatorenal syndrome Mite allergy Anal cancer Epithelioid sarcoma Encephalitis Japanese B Antithrombin III deficiency More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. IRCCS Humanitas Research Hospital

IRCCS Humanitas Research Hospital

Via Alessandro Manzoni 56, Rozzano, 20089, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • Study of TAR-200 and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Not Undergoing Radical Cystectomy

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Cetrelimab
    • Cisplatin
    • Gemcitabine
    Austria Belgium Czechia France Germany Greece +4

  • Long-Term Safety Study of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Obefazimod
    Austria Belgium Czechia France Germany Hungary +5

  • Study of Disitamab Vedotin and Pembrolizumab for Patients with Untreated Advanced Urothelial Cancer Expressing HER2

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Disitamab Vedotin
    • Carboplatin
    • Cisplatin
    Austria Belgium Czechia France Greece Hungary +7

  • Study of Amivantamab and Lazertinib Combination vs. Osimertinib vs. Lazertinib for First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Amivantamab
    • Lazertinib
    • Osimertinib
    Belgium France Germany Hungary Italy The Netherlands +3

  • Study of Sasanlimab with BCG or Alone for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Not Responding to BCG

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Sasanlimab
    Belgium France Germany Italy Poland Spain

  • Study of Letetresgene Autoleucel for Patients with Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Myxoid liposarcoma
    • Round cell liposarcoma
    • Synovial sarcoma
    Investigated Drugs:
    • Letetresgene Autoleucel
    France Italy The Netherlands Spain

  • Study on Reduced Dose of Alteplase for Patients with Intermediate-High-Risk Acute Pulmonary Embolism

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Pulmonary embolism
    Investigated Drugs:
    • Alteplase
    Austria France Germany Italy The Netherlands Poland +2

  • Study Comparing Lorlatinib and Crizotinib for Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    • Non-small cell lung cancer metastatic
    • Non-small cell lung cancer stage IV
    Investigated Drugs:
    • Lorlatinib
    Belgium Czechia France Germany Italy The Netherlands +2

  • Study on the Safety and Anti-tumor Effects of GEN1042 Alone or with Pembrolizumab and Chemotherapy in Patients with Advanced Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Tecaginlimab
    • Carboplatin
    • Cisplatin
    Denmark France Germany Italy Spain

  • Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Ulcerative Colitis

    Not recruiting

    3 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Risankizumab
    Austria Belgium Bulgaria Croatia Czechia France +13
Previous Page
1 … 54 55 56 57 58 … 69
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!